#1Investor Science Event Getting ahead of anaemia due to chronic kidney disease ASN Kidney Week 2021 7 November 2021 gsk#2Cautionary statement regarding forward-looking statements gsk This presentation may contain forward-looking statements. Forward-looking statements give the Group's current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as 'anticipate', 'estimate', 'expect', 'intend', 'will', 'project', 'plan', 'believe', 'target' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and financial results. Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements. Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group's control or precise estimate. The Group cautions investors that a number of important factors, including those in this presentation, could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under Item 3.D 'Risk factors' in the Group's Annual Report on Form 20-F for FY 2020 and any impacts of the COVID-19 pandemic. Any forward-looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge and information available to the Directors on the date of this presentation. A number of adjusted measures are used to report the performance of our business, which are non-IFRS measures. These measures are defined and reconciliations to the nearest IFRS measure are available in our third quarter 2021 earnings release and Annual Report on Form 20-F for FY 2020. All expectations and targets regarding future performance and the dividend should be read together with the section "Outlook, assumptions and cautionary statements" on pages 60 and 61 of our third quarter 2021 earnings release. 2#3Speakers 1. Dr Hal Barron 2. Dr Ajay Singh 3. Luke Miels 1 2 3 gsk 3#4Agenda Daprodustat: a potential best-in-class treatment Dr Hal Barron ASCEND Phase III programme Dr Ajay Singh Commercial opportunity Q&A Luke Miels Dr Hal Barron Luke Miels Chris Corsico Dr Ajay Singh John Lepore gsk 4#5Daprodustat: a potential best-in-class treatment Dr Hal Barron, Chief Scientific Officer and President, R&D gsk 5#6Daprodustat Potential best-in-class treatment for patients with anaemia due to CKD1 Nobel prize-winning science with OH OH Pro Pro NORMOXIA PATHWAY HIFa Asm Daprodustat (HIF-PHI) HIF Prolyl Hydroxylase-1,2,3 Enzyme Pro Pro HIFG Asn HYPOXIA PATHWAY Pro Pro Ubiquitin- mediated degredation of HIFa Nucleus HiFa Asni Transcription of HIF-responsive genes HIFE 300 Moni ASCEND2: Phase III clinical development programme with large geographical reach • • >8,000 patients with anaemia due to CKD3 in five Phase III trials Consistent clinical trial programme: • Active control (injectable ESA4) • One global Hb5 target range (10-11 g/dl) • Standardised patient management methods6 • Trial design and primary MACE7 end-point aligned with global regulators • No meta-analysis required •Studies in dialysis (peritoneal, and haemodialysis) and non-dialysis High unmet medical need gsk >700 million people suffer from chronic kidney disease worldwide 0000000 One in seven patients suffer from anaemia of CKD where the current standard of care is administered via subcutaneous injection or as part of dialysis 1. Chronic kidney disease 2. Anaemia Studies in Chronic Kidney Disease: Erythropoiesis via a Novel prolyl hydroxylase inhibitor Daprodustat 3. Presented at American Society of Nephrology Kidney Week 2021: Singh AK, et al. FR-OR66 and PO0465; Coyne DM, et al PO0487; and Johensen KL, et al FR-CR53 4. Erythropoiesis-stimulating agents 5. Haemoglobin 6. Dose adjustment algorithms, iron management criteria and anaemia rescue algorithms 7. Evaluating a composite of all-cause mortality, stroke and myocardial infarction 8. The Lancet, The Global Burden of Chronic Kidney Disease published in February 2020. 6#7gsk ASCEND Phase III programme Dr Ajay K. Singh, Senior Associate Dean for Postgraduate Medical Education from Harvard Medical School, and Principal Investigator 7#8ASCEND Clinical Trial Program The Anemia Studies in Chronic Kidney Disease: Erythropoiesis via a Novel prolyl hydroxylase inhibitor Daprodustat (ASCEND) Phase III program investigated the efficacy and safety profile of daprodustat across Dialysis trials ascend DIALYSIS a spectrum of patients with CKD Cardiovascular Outcome Trials (CVOTS) Non-dialysis trials asceND ND NON-DIALYSIS asceNDID INCIDENT DIALYSIS asceND TD THREE-TIMES WEEKLY DOSING IN DIALYSIS ASCEND Phase III Program Com asceND/NHQ NON-DIALYSIS, HEMOGLOBIN & QUALITY OF LIFE CKD, chronic kidney disease; D dialysis; Hb, hemoglobin; ID, incident dialysis; ND, non-dialysis; NHQ, TD, three times a week dosing. 8#9ASCEND-D and -ND: Trial Design Event-driven, open-label, randomized, active-controlled, parallel-group, multicenter, Phase 3 trials ASCEND-D and ASCEND-ND accepted for publication Co-primary Endpoints Open-label* 1:1 randomization 4-week screening 4-week placebo run-in R Daprodustat, oral, daily Hb treatment target: 10.0-11.0 g/dL Iron management protocol applied to both arms ESA+ (D) Darbepoetin alfa, SC (ND) ASCEND-ND: Key Entry Criteria Mean change in Hb from baseline to the average during the primary evaluation period (Week 28 through Week 52) Time to first MACE+ (target 664 adjudicated first events) ASCEND-D: Key Entry Criteria ≥18 years of age Randomization Hb criteria: Hb 8.0-11.5 g/dL ESA users Dialysis (HD/PD) >90 days prior to screening Iron replete: Ferritin >100 ng/mL; TSAT >20% • ≥18 years of age CKD Stage 3-5 Randomization Hb criteria: - Hb 8.0-10.0 g/dL, if not using ESAs - Hb 8.0-11.0 g/dL, if using ESAs Not on dialysis and no plans to start within 90 days Iron replete: Ferritin >100 ng/mL; TSAT >20% *The sponsor, steering committee and endpoint adjudication committee remained blind to aggregate treatment assignment throughout the trial. +Epoetin alfa (IV; HD patients) or darbepoetin alfa (SC; PD patients). #MACE: composite of all-cause mortality, a non-fatal myocardial infarction, or a non-fatal stroke. CKD, chronic kidney disease; ESA, erythropoiesis-stimulating agent; Hb, hemoglobin; HD, hemodialysis; IV, intravenous; MACE, major adverse cardiovascular event; PD, peritoneal dialysis; R, randomization; SC, subcutaneous; TSAT, transferrin saturation. 9#10Patient Disposition ITT Population Few patients withdrew and withdrawal rates were similar across treatment groups Premature discontinuation of randomized treatment was balanced across treatment groups Known vital status was high in both trials across both treatment groups ESA asceND ND NON-DIALYSIS asceND D Darbepoetin Daprodustat Daprodustat alfa DIALYSIS Randomized, n 2964 Randomized, n 3872 Intent-to-treat, n 1487 1477 Intent-to-treat, n 1937 1935 Withdrew from trial, % 8 8 Withdrew from trial, % 3 Completed the trial 92 Prematurely discontinued RT, % 53 Did not prematurely discontinue RT 47 47 Known vital status, % 98 Unknown vital status 2 28 N 92 Completed the trial 97 97 53 Prematurely discontinued RT, % Did not prematurely discontinue RT 38 62 98 Known vital status, % 99 310022 38 62 99 2 Unknown vital status <1 <1 ITT, intent-to-treat; RT, randomized treatment. Note: In ASCEND-D, 5 daprodustat and 3 ESA patients were randomized but never treated. In ASCEND-ND, 2 darbepoetin alfa patients were randomized but never treated. 10#11WK 40 WK 28 WK 16 WK 4 DAY 1 SCR WK-8 No. of patients Daprodustat ESA 1477 1475 1449 1381 1323 1270 1225 1175 1125 1059 998 838 601 419 230 WK 64 WK 76 WK 52 1487 1485 1453 1403 1336 1274 1241 1191 1138 1092 1039 863 612 432 248 Co-primary Efficacy Endpoint: ASCEND-D Mean Hb change from baseline to the evaluation period (Weeks 28-52) - ITT Population Hb concentration (g/dL) Daprodustat was noninferior to ESA for mean change in Hb from baseline to the evaluation period (Weeks 28-52) 12 asceND D ✰ Daprodustat ESA 11.5 11 10.5 10 9.5 9 DIALYSIS EP Prespecified NI margin: -0.75 g/dL Adjusted Mean Treatment Difference (95% CI)* 0.18 (0.12, 0.24) Noninferiority was achieved because the lower limit of the 95% CI of the treatment difference was greater than the prespecified noninferiority margin of -0.75 g/dL WK 148 WK 136 WK 112 WK 124 WK 100 WK 88 *Based on an ANCOVA model using observed and imputed data with terms for treatment, baseline hemoglobin, dialysis type and region. Error bars indicate 95% CI. Post-randomization values include on- and off- treatment values. Visits on or before Day 1 include only pre-treatment values. Horizontal reference lines represent the Hb analysis range (10-11.5g/dL). The Hb target range for dose changes is 10-11g/dL. Vertical dotted lines represent the EP. Cl, confidence interval; EP, evaluation period; EOS, end of study; ESA, erythropoiesis-stimulating agent; FU, follow up; Hb, hemoglobin; ITT, intent-to-treat; NI noninferiority; SCR screening; Wk, week. FU EOS 862 639 839 628 11#12Co-primary Efficacy Endpoint: ASCEND-ND Mean Hb change from baseline to the evaluation period (Weeks 28-52) – ITT Population Daprodustat was noninferior to darbepoetin alfa for mean change in Hb from baseline to the evaluation period (Weeks 28-52) 12 ASCEND ND ✰ Daprodustat Darbepoetin alfa 12.5 Hb concentration (g/dL) NON-DIALYSIS 11.5 11- 10.5 10 9.5 9 8.5 EP WK 148 WK 136 WK 124 WK 112 WK 100 WK 88 WK 76 WK 64 WK 52 WK 40 WK 28 WK 16 WK 4 DAY 1 SCR WK-8 FU EOS Prespecified NI margin: -0.75 g/dL Adjusted Mean Treatment Difference (95% CI)* 0.08 (0.03, 0.13) Noninferiority was achieved because the lower limit of the 95% CI of the treatment difference was greater than the prespecified noninferiority margin of -0.75 g/dL No. of patients Daprodustat Darbepoetin alfa 1936 1932 1866 1705 1511 1364 1254 1100 961 832 725 587 453 349 243 1935 1933 1867 1697 1506 1398 1243 1100 952 835 727 602 482 378 272 1276 1056 1278 1043 *Based on an ANCOVA model using observed and imputed data with terms for treatment, baseline hemoglobin, current ESA use and region. Error bars indicate 95% CI. Post-randomization values include on- and off- treatment values. Visits on or before Day 1 include only pre-treatment values. Horizontal reference lines represent the Hb analysis range (10-11.5g/dL). The Hb target range for dose changes is 10-11g/dL. Vertical dotted lines represent the EP. Cl, confidence interval; EP, evaluation period; EOS, end of study; ESA, erythropoiesis-stimulating agent; FU, follow up; Hb, hemoglobin; ITT, intent-to-treat; NI noninferiority; SCR screening; Wk, week. 12#13First Occurrence of Adjudicated MACE During the Time Period for Follow-up of CV Events - ITT Population asceND DIALYSIS 1.0 0.9 Daprodustat ESA NON-DIALYSIS asceND ND Daprodustat Darbepoetin alfa 1.0- HR (95% CI): 0.93 (0.81, 1.07) 0.9 HR (95% CI): 1.03 (0.89–1.19) Cumulative incidence 0.8 L Non-fatal stroke Daprodustat (N=1487) ESA (N=1477) 0.7 First occurrence of adjudicated MACE, 374 (25.2) 394 (26.7) 0.6 n (%) All-cause mortality 244 (16.4) 233 (15.8) 0.5 Non-fatal myocardial infarction 101 (6.8) 126 (8.5) 0.4 29 (2.0) 35 (2.4) 0.3 0.2 0.1 0.0 0 4 8 Cumulative incidence 0.8- Daprodustat Darbepoetin alfa (N=1937) (N=1935) 0.7- First occurrence of adjudicated MACE, 378 (19.5) 371 (19.2) 0.6- n (%) All-cause mortality 252 (13.0) 259 (13.4) 0.5- Non-fatal myocardial infarction 96 (5.0) 91 (4.7) 0.4- Non-fatal stroke 30 (1.5) 21 (1.1) 0.3 0.2- 0.1- 0.0- T T T 12 16 20 Months since randomization T 24 28 32 - 32 36 0 4 8 12 16 20 24 28 32 36 Months since randomization Patients at risk Daprodustat 1487 1425 1352 1297 1240 1181 1129 861 559 250 ESA 1477 1427 1348 1271 1217 1170 1108 836 525 245 Patients at risk Daprodustat Darbepoetin alfa 1937 1834 1601 1414 1207 1024 840 647 468 288 1935 1825 1582 1412 1221 1038 843 660 474 291 Noninferiority was achieved because the upper boundary of the 95% CI of the HR was lower than the pre-specified NI margin of 1.25 HR estimated using a Cox proportional hazards regression model with treatment group, dialysis type (ASCEND-D) or baseline ESA use (ASCEND-ND) and region as covariates. A HR <1 indicates a lower risk with daprodustat compared with ESA/darbepoetin alfa. Note: y-axis scale may differ from those in the primary publications. Cl, confidence interval; CV, cardiovascular; ESA, erythropoiesis-stimulating agent; HR, hazard ratio; ITT, intent-to-treat; MACE, major adverse cardiovascular event. 13#14MACE Supplementary Analyses Supplementary MACE analyses were generally consistent with noninferiority conclusions from the primary analysis, except the ASCEND-ND on-treatment MACE analysis Daprodustat ESA better better No. of Patients Treatment /Total No. asceND D First occurrence Daprodustat 374/1487 DIALYSIS Analysis NI margin = 1.25 Hazard Ratio (95% CI) 0.93 (0.81, 1.07) asceND ND NON-DIALYSIS Analysis Daprodustat better No. of Patients Treatment /Total No. Darbepoetin alfa better NI margin = 1.25 Hazard Ratio (95% CI) 1.03 (0.89, 1.19) MACE (primary) ESA 394/1477 First occurrence Daprodustat 378/1937 MACE (primary) Darbepoetin 371/1935 alfa First occurrence Daprodustat 255/1482 0.96 (0.81, 1.14) First occurrence Daprodustat 274/1937 1.40 (1.17, 1.68) on-treatment ESA 271/1474 on-treatment Darbepoetin 202/1933 MACE MACE alfa First occurrence Daprodustat 363/1487 MACE, excl. 385/1477 0.92 (0.80, 1.07) ESA COVID-19 First occurrence Daprodustat 345/1937 MACE, excl. Darbepoetin 339/1935 alfa 1.03 (0.88, 1.19) COVID-19 MACE First occurrence Daprodustat 326/1487 MACE, until ESA 338/1477 664th MACE 0.6 0.8 1 1.2 1.4 Hazard ratio (95% CI) MACE 0.95 (0.81, 1.10) First occurrence Daprodustat 378/1937 MACE with Darbepoetin 371/1935 additional covariates alfa 1.01 (0.88, 1.17) 0.5 1 1.5 Hazard ratio (95% CI) 2 Note: With the exception of the on-treatment analyses, all analyses follow the "ITT approach" and use both on- and off-treatment MACE events. On-treatment: from treatment start to the earlier of [28 days after the participant's last dose of randomized treatment (last dose date + 28 days), or date of study completion/withdrawal]. HR estimated using a Cox proportional hazards regression model with treatment group, dialysis type (ASCEND-D) or baseline ESA use (ASCEND-ND) and region as covariates. A HR <1 indicates a lower risk with daprodustat compared with ESA/darbepoetin alfa. Cl, confidence interval; ESA, erythropoiesis-stimulating agent; MACE, major adverse cardiovascular event; NI, noninferiority. 14#15Principal Secondary Endpoints Hazard ratio (95% CI)+ 0.93 (0.81, 1.07) Principal secondary endpoints did not meet multiplicity-adjusted statistical significance for superiority* asceND D DIALYSIS MACE (superiority) asceND ND NON-DIALYSIS MACE (superiority) Hazard ratio (95% CI)+ 1.03 (0.89, 1.19) MACE + thromboembolic events (DVT, PE, VAT) 0.88 (0.78, 1.00) MACE + thromboembolic events (DVT, PE, VAT) 1.06 (0.93, 1.22) MACE + hospitalization for heart failure 0.97 (0.85, 1.11) MACE + hospitalization for heart failure 1.09 (0.95, 1.24) Adjusted Mean Treatment Difference daprodustat-ESA (95% CI)* Hazard ratio (95% CI)$ -9.1 (-18.4, 0.2) On-treatment average monthly IV iron dose (mg) from baseline to Week 52 CKD progression (40% decline in eGFR OR ESRD, i.e., chronic dialysis, not initiating dialysis when indicated or kidney transplant) 0.98 (0.84, 1.13) *Holm-Bonferroni multiplicity adjustment used for principal secondary endpoints. *HR estimated using a Cox proportional hazards regression model with treatment group, dialysis type (ASCEND-D) or baseline ESA use (ASCEND-ND) and region as covariates. *Based on an ANCOVA model with terms for treatment, baseline monthly IV iron dose, dialysis type and region; $Subdistribution hazard ratio estimated using Fine & Gray's proportional subdistribution hazard regression model with treatment group, baseline ESA use, and region as covariates. A HR <1 indicates a lower risk with daprodustat compared with ESA/darbepoetin alfa. Cl, confidence interval; CKD, chronic kidney disease; DVT, deep vein thrombosis; eGFR, estimated glomerular filtration rate; ESA, erythropoiesis-stimulating agent; ESRD, end stage renal disease; HR, hazard ratio; IV, intravenous; MACE, major adverse cardiovascular event; PE, pulmonary embolism; VAT, vascular access thrombosis. 15#16Adverse Events Safety population reporting treatment-emergent events AE and SAE rates were similar between treatment groups in both studies Rates of AESIs were generally similar between treatment groups in both studies asceND D DIALYSIS Daprodustat (N=1482) ESA (N=1474) asceND ND NON-DIALYSIS Rate of AEs Rate of SAES 88% 85% Rate of AES 52% 51% Rate of SAES Darbepoetin Daprodustat (N=1937) alfa (N=1933) 80% 77% 44% 36% Adverse Events of Special Interest (AESIs) undergoing further investigation: Esophageal and gastric 4.0% [60] 5.5% [81] erosions, % [n] Esophageal and gastric erosions, % [n] 3.6% [70] 2.1% [41] Cancer-related mortality and tumor progression and recurrence, % [n] 3.2% [47] 3.5% [51] Cancer-related mortality and tumor progression and recurrence, % [n] 3.7% [72] 2.5% [49] Safety population: all randomized patients who received at least one dose of randomized treatment. Treatment-emergent adverse events are reported which start or worsen on or after the participant's treatment start date and on or before the day after the participant's last dose of randomized treatment. Adverse events of special interest were investigator reported events and were not adjudicated. They were defined for da produstat based on data from non-clinical and clinical studies, current information about HIF-associated pathophysiology, and identified risks for ESAs. A programmatic approach for these potential events was implemented using a broad set of terms of interest. AE, adverse event; AESI, adverse event of special interest; ESA, erythropoiesis-stimulating agent; HIF, hypoxia-inducible factor; SAE, serious adverse event. 16#17ASCEND Program-Level Cardiovascular Safety Data MACE profile was generally consistent across treatment groups in all trials* Patients with events n/N (%) Rate per 100 PY (95% CI) Favors Daprodustat Favors ESA MACE Daprodustat ESA+ Daprodustat ESA+ ASCEND-ND 378/1937 (19.5) 374/1487 371/1935 (19.2) 394/1477 10.86 (9.80, 12.02) 10.63 H Absolute rate difference per 100 PY (95% CI) 0.23 (-1.31, 1.77) (9.58, 11.77) 11.07 11.86 ASCEND-D -0.78 (-2.41, 0.84) HH (25.2) (26.7) (9.98, 12.26) (10.72, 13.09) 19/157 15/155 ASCEND-ID (12.1) (9.7) 33/270 14/137 ASCEND-TD (12.2) (10.2) 11.65 (7.02, 18.20) 12.30 (8.46, 17.27) 9.24 (5.17, 15.24) 2.41 (-4.61, 9.43) 10.02 (5.48, 16.81) 2.28 (-4.44, 9.00) 0 5 10 15 20 -10 -5 0 5 10 15 Rate per 100 PY (95% CI) Absolute rate difference per 100 PY (95% CI) First MACE rates in ASCEND-NHQ (28 weeks): 4.9% daprodustat; 6.2% placebo *Smaller trials (ASCEND-ID, ASCEND-TD and ASCEND-NHQ) reported MACE but were not designed for formal MACE evaluation; †Darbepoetin alfa (ASCEND-D, -ND, -ID), epoetin alfa (ASCEND-D, -TD). 17#18ASCEND Program-Level Cardiovascular Safety Data MACE components were generally consistent across treatment groups in all trials* Patients with events n/N (%) Rate per 100 PY (95% CI) Daprodustat Favors Favors ESA Daprodustat ESA+ Daprodustat ESAT All-cause mortality ASCEND-ND 301/1937 (15.5) 294/1487 298/1935 (15.4) 300/1477 8.35 (7.43, 9.35) 8.27 (7.35, 9.26) ASCEND-D (19.8) (20.3) 8.32 (7.39, 9.32) 8.59 Absolute rate difference per 100 PY (95% CI) 0.08 (-1.25, 1.41) -0.28 (-1.63, 1.08) (7.65, 9.62) 17/157 12/155 ASCEND-ID (10.8) 18/270 ASCEND-TD (6.7) (7.7) 10/137 (7.3) 10.32 (6.01, 16.52) 7.23 (3.74, 12.63) 6.47 (3.84, 10.23) 7.04 (3.37, 12.94) 3.08 (-3.30, 9.47) -0.56 (-5.85, 4.72) Myocardial infarction ASCEND-ND 103/1937 (5.3) 114/1487 97/1935 (5.0) 137/1477 2.94 (2.40, 3.56) 2.76 (2.24, 3.36) 0.18 (-0.61, 0.97) HH ASCEND-D (7.7) (9.3) 3.34 (2.76, 4.01) 4.08 H◉ -0.74 (-1.66, 0.18) (3.43, 4.83) HH 5/157 5/155 ASCEND-ID (3.2) 11/270 (3.2) 5/137 3.07 (1.00, 7.15) 3.08 -0.01 (-3.82, 3.80) (1.00, 7.19) ASCEND-TD (4.1) (3.6) 4.03 (2.01, 7.21) 3.58 (1.16, 8.35) 0.45 (-3.48, 4.39) Stroke ASCEND-ND 45/1937 (2.3) 43/1487 34/1935 (1.8) 51/1477 1.26 (0.92, 1.69) 0.95 (0.66, 1.33) 0.31 (-0.18, 0.80) K ASCEND-D (2.9) (3.5) 1.23 (0.89, 1.66) 1.48 (1.10, 1.94) H◉ -0.25 (-0.79, 0.30) H+ 1/157 1/155 0.61 ASCEND-ID (0.6) (0.6) (0.02, 3.38) 0.60 (0.02, 3.36) 0.00 (-1.67, 1.68) 8/270 0/137 ASCEND-TD (3.0) (0.0) 2.92 (1.26, 5.76) 0.00 (0.00, 2.60) 2.92 (0.90, 4.95) 0 5 10 15 20 -10 -5 0 5 10 15 Rate per 100 PY (95% CI) *Smaller trials (ASCEND-ID, ASCEND-TD and ASCEND-NHQ) reported MACE but were not designed for formal MACE evaluation; *Darbepoetin alfa (ASCEND-D, -ND, -ID), epoetin alfa (ASCEND-D, -TD). Absolute rate difference per 100 PY (95% CI) 18#19Summary and Conclusions - - Daprodustat was as effective as conventional ESA therapy in treating anemia of CKD Daprodustat was noninferior to ESA with respect to CV safety and no new safety signals were observed Daprodustat could represent an oral alternative to ESA for treating anemia of CKD in both dialysis and non-dialysis patients 19 AE, adverse events; CKD, chronic kidney disease; CV, cardiovascular; MACE, major adverse cardiovascular event#20Commercial opportunity Luke Miels, Chief Commercial Officer gsk 20 20#21The prevalence of anaemia increases as CKD progresses; it is associated with an increased risk of hospitalisation, cardiovascular complications and death gsk North America 30 million CKD prevalence Europe 25 million CKD prevalence 16 million Stages 3-5 19 million Treating patients with anaemia due to CKD Stages 3-5 Diagnosed Average treatment Stage of CKD Kidney function % patients duration (m) (years) Primary care physician and Nephrologist Stage 3a 45-59 4.4 7.9 Stage 3b 30-44 5.6 5.0 Stage 4 15-29 1.3 4.2 Asia Nephrologist Stage 5 <15% 0.5 0.8 367 million CKD prevalence 123 million Stages 3-5 Source: 1. NHANES 2016 data accessed via Centers for Disease Control and Prevention. CKD Surveillance System-United States; website: http://www.cdc.gov/ckd; 2. 2018 USRDS Annual data report-Volume 2: ESRD in the US 3. Lancet: Global, regional and national burden of chronic kidney disease, 1990-2017; 4. The prevalence of Chronic Kidney Disease in Asia, Liyanage T, Toyama T, ISN WCN 2020. 5 Spherix RealWorld Dynamix ND Patient Audit Neph and PCP-2019, 6: GSK internal materials, 7. Dowling TC. Am J Health Syst Pharm 2007;64(13 Suppl 8):S3-7., Schmidt RJ, Dalton CL. Osteopath Med Prim Care 2007;1:14. 21#22HIF-PHI¹ class could become the new standard of care Daprodustat has the potential to deliver patient benefit across populations Non-dialysis dependent >1 million Patients treated in the US and Europe c.30% Patients with Hb <10g/dl treated with ESA 54% Treatment discontinuation in one year Dialysis dependent gsk >850 thousand Patients treated in the US and Europe c.12% Patients treated with home dialysis (expected to grow to 25% by 2025) c.12% ESA hypo responders 1. Hypoxia-inducible factor prolyl hydroxylase Inhibitors. Source: Epidemiology data derived from multiple sources, including: 1. https://www.thelancet.com/article/S0140-6736(20)30045-3/fulltext 2. Prevalence of Anemia in Chronic Kidney Disease in the United States (nih.gov) 3. Nephrol Dial Tranplant 2002, Suppl 11:44-6 4. https://www.nature.com/articles/s41598-020-79254-6, 5CKDopps. Sci Rep 11, 1784 (2021). https://doi.org/10.1038/s41598-020-79254-6, Spherix RealWorld Dynamix 20Q2 report. 22#23Japan: Duvroq has achieved market-leading share Encouraging launch despite being second to market Leading market share Translating success in Japan to global expansion Strong momentum across populations • gsk 75% of patients switching from ESA to Duvroq JP¥ 3,000 2,500 2,000 1,500 1,000 500 0 100% 80% 60% 40% . 25% new to treatment 46.8% 30.7% • Rx to patients in both DD (40%) and NDD (60%) Early engagement enabled smooth commercial transition • . Started early conversations with US commercial providers and large dialysis centers Encouraged by positive initial feedback and intent to include PHIs in treatment paradigm Will continue dialogue as we move closer to filing 20% 25W · Μεε 41W- 49W- 57W 65W- 73W 81W- M68 97W- 105W- 113W 0% 20.1% Jul-20 Duvroq Competitor 3 Oct-20 Competitor 1 Jan-21 ⚫ Competitor 2 Apr-21 Jul-21 Competitor 4 Competitor 1 Competitor 2 Duvroq (dapro) Source: IQVIA JPM Monthly model, September flash data from IQVIA JPM flash. Source: IQVIA JPM Monthly model, September flash data from IQVIA JPM flash. 23#24• • Daprodustat: an innovative, convenient oral treatment for patients with anaemia due to CKD Strong clinical data supports competitive commercial profile Convenient oral option for non-dialysis and dialysis patients Flexible dosing: QD1 or TIW² with iron and phosphate binders Predictable Hb increase and maintenance within target level Improvements in QOL³ including fatigue (SF-36 vitality score) Significant market opportunity >₤2 billion >£2 US ESA CKD market >₤1 billion Europe ESA CKD market gsk Leveraging experience to deliver commercial success • Investing behind internal capabilities • >900 specialty experts hired since 2017 Established leadership position with nephrologists from Benlysta LN launch H1 2022: regulatory submissions (US, EU) 1. Once daily 2. Three times weekly 3. Quality of life. 24#25Q&A gsk 25